Literature DB >> 1572087

Prolonged clinically asymptomatic evolution after HIV-1 infection is marked by the absence of complement C4 null alleles at the MHC.

F Hentges1, A Hoffmann, F Oliveira de Araujo, R Hemmer.   

Abstract

The length of time after which persons infected with HIV-1 progress to AIDS is variable. Certain alleles at the MHC have been shown to influence negatively the clinical outcome of HIV-1-infected persons and to be associated with special clinical manifestations. We investigated the MHC class I, class II and class III antigens in 54 Caucasian HIV-1-infected persons. The MHC profile of individuals with a prolonged period before AIDS is marked by a lower frequency of C4 null alleles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1572087      PMCID: PMC1554293          DOI: 10.1111/j.1365-2249.1992.tb03067.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Phenotyping of human complement component C4, a class-III HLA antigen.

Authors:  E Sim; S J Cross
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

2.  Usefulness of densitometry in typing of human complement component C4.

Authors:  J Kramer; E Gyódi; G Füst
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Susceptibility to HIV infection and AIDS in Italian haemophiliacs is HLA associated.

Authors:  G Fabio; R S Smeraldi; A Gringeri; M Marchini; P Bonara; P M Mannucci
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

4.  Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation.

Authors:  P A Gatenby; J E Barbosa; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

5.  Serial CD4 lymphocyte counts and development of AIDS.

Authors:  A N Phillips; C A Lee; J Elford; G Janossy; A Timms; M Bofill; P B Kernoff
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

6.  C4 allotyping on plasma or serum: application to routine laboratories.

Authors:  W J Zhang; P H Kay; T J Cobain; R L Dawkins
Journal:  Hum Immunol       Date:  1988-03       Impact factor: 2.850

7.  Major histocompatibility complex genes influence the outcome of HIV infection. Ancestral haplotypes with C4 null alleles explain diverse HLA associations.

Authors:  P U Cameron; S A Mallal; M A French; R L Dawkins
Journal:  Hum Immunol       Date:  1990-12       Impact factor: 2.850

8.  HLA-A,B,C and DR antigen frequencies in acquired immunodeficiency syndrome (AIDS) patients with opportunistic infections.

Authors:  M S Pollack; J Gold; C E Metroka; B Safai; B Dupont
Journal:  Hum Immunol       Date:  1984-10       Impact factor: 2.850

9.  A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study.

Authors:  R A Kaslow; R Duquesnoy; M VanRaden; L Kingsley; M Marrari; H Friedman; S Su; A J Saah; R Detels; J Phair
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  3 in total

1.  Immunoglobulins and complement factor C4 in adult rhinosinusitis.

Authors:  M Seppänen; J Suvilehto; M-L Lokki; I-L Notkola; A Järvinen; H Jarva; I Seppälä; O Tahkokallio; H Malmberg; S Meri; V Valtonen
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Complement activation by human monoclonal antibodies to human immunodeficiency virus.

Authors:  G T Spear; D M Takefman; B L Sullivan; A L Landay; S Zolla-Pazner
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

3.  Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Authors:  Erin Mehlhop; Michael S Diamond
Journal:  J Exp Med       Date:  2006-05-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.